• Report Adverse Event or Product Quality Complaint
  • Global Site
AstraZeneca Medical Information
  • Prescribing Information
  • Resources
    • Congress Library
    • Our Pipeline
    • AZ Clinical Trials
    • Externally Sponsored Scientific Research
  • Connect
    • Send MIR
    • Give Feedback

Search Medical Information

World Conference on Lung Cancer (WCLC) 2025

September 06 - 09, 2025

  1. Datopotmab deruxtecan
  2. Durvalumab
  3. Osimertinib
  4. Rilvegostomig
  5. Savolitinib
  6. Trastuzumab Deruxtecan
  7. Volrustomig

ppt

Intracranial Efficacy of Datopotamab Deruxtecan (Dato DXd) in Patients With Advanced/metastatic NSCLC in TROPION-Lung01

ppt

Patterns of Progression and Recurrence with Perioperative Durvalumab in Patients with Resectable NSCLC from AEGEAN

ppt

Detection of ctDNA Prior to Neoadjuvant Osimertinib Treatment Correlates With Decreased EFS in EGFR-Mutated NSCLC

ppt

Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights From the ADAURA Study

pdf

Treatment Patterns and Clinical Outcomes in South Korean Patients With Unresectable Stage III EGFRm NSCLC Undergoing CRT

pdf

Stereotactic Body Radiation Therapy for Medically Inoperable Stage I/II EGFRm NSCLC: Global, Multicenter, Retrospective Study

pdf

Real-World (RW) Study of Biomarker Testing Patterns Among Patients With Early-Stage Resected NSCLC in the United States

ppt

First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival

ppt

First-Line Osimertinib ± Platinum-Pemetrexed in EGFR-Mutated Advanced NSCLC: FLAURA2 Clinical Outcomes by EGFRm Subtype

ppt

First-Line Osimertinib ± Platinum-Pemetrexed Chemotherapy for EGFR-Mutated Advanced NSCLC: FLAURA2 Non-Asian Country Cohort

ppt

COMPEL: Osimertinib + Platinum-Based Chemotherapy in Patients With EGFRm Advanced NSCLC and Progression on 1L Osimertinib

pdf

A Phase 3, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for First-line Treatment of Patients with Metastatic Squamous Non-small-cell Lung Cancer Whose Tumors Express PD-L1

ppt

Rilvegostomig enhances ex vivo immune activation of patient resected NSCLC tumors to greater levels than clinically approved PDx monotherapies or combinations of anti-PD1 and anti-TIGIT bivalent antibodies

ppt

Osimertinib + Savolitinib in EGFRm Advanced NSCLC With MET Overexp And/Or Amp Post-Progression on Osimertinib: SAVANNAH PROs

ppt

SAVANNAH: Biomarker Concordance and Acquired Resistance in Patients with EGFRm MET-OverExp and / or Amp NSCLC

ppt

Frontline Treatment Duration in MET-Amplified NSCLC After Third-Generation Egfr-TKI Failure: SACHI Study Insights

ppt

Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients With or Without Prior Immunotherapy

pdf

Trastuzumab Deruxtecan in Chinese Patients With Pretreated HER2-mutant Non-small cell Lung Cancer: DESTINY-Lung05 Results

pdf

Trastuzumab Deruxtecan + Pembrolizumab as First-line Treatment in HER2-overexpressing, PD-L1 TPS <50% NSCLC (DESTINY-Lung06)

pdf

Concordance of HER2 Protein Overexpression by IHC and ERBB2 Gene Amplification by NGS in Lung Cancer

pdf

Phase 3 eVOLVE-Lung02 Trial of Volrustomig + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic NSCLC with PD-L1 TC <50%

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

AstraZeneca Logo

This platform is provided as service to healthcare professionals by AstraZeneca Philippines, for medical educational purposes only.

©2024 AstraZeneca. All rights reserved.

PH-10554.

Last Updated 5/24

Contact Us

About Us

AstraZeneca.com

Survey Feedback

Privacy Notice

Legal Notice

Cookie Notice

Global Site

Report Adverse Event or Product Quality Complaint

Privacy NoticeLegal NoticeCookie Notice

Welcome to AstraZeneca Philippines Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the Philippines, for medical educational purposes only. AstraZeneca does not engage in the promotion of unregistered products or unapproved indications. The dissemination of this information may be subject to different medical and regulatory requirements in other countries

Are you a healthcare professional practicing in the Philippines?

No